The MOCA Story

Our journey into the cannabis industry commenced in earnest when in early 2016, when the Australian Government announced the birth of the medical cannabis industry in Australia. Legislation to enable the cultivation of cannabis for medicinal and related research purposes in Australia was passed by Parliament on 29 February 2016. The amendments relating to licensing came into effect on 30 October 2016.

This curious news sparked an intensive 2 year research for the directors, into why marijuana (which had been, up until that time, considered, among other things, an illegal and illicit drug), was now being reclassified as a medicine?

After, thousands of hours of research in academic journals, visiting academic professors in Europe and inspecting several cannabis cultivation facilities in Canada the founders of the company had our answer. The startling explanation to this question of why cannabis went from, supposedly gateway drug to being considered one of the most important medicines of the 21st century.

MOCA Vision and Philosophy

The company brings together a team of passionate professionals with over 20 years’ experience in the cannabis industry.

MOCA’s will become one of the leading medical cannabis companies in the world and will lead the way in quality, safety and ethical conduct. We are always seeking the best partners and staff so get in touch if you are passionate and excellent in what you do.

MOCA Research Team

Company Directors Emanuela Ispani (centre) and Alessandro Sorbello (right) at cannabis extraction facility in The Nederlands 2017.

A Research Mission

The answer to this medical focused question is, that a series of scientific discoveries made by Dr Raphael Mechoulam an Israeli researcher toward the end of the 20th century revealed that human beings have what is now known as an endocannabinoid system, also known as ECS. Like other crucial systems in the human body, the ECS plays an important role, in fact perhaps one of the most fundamental roles in keeping humans healthy. Because, the sole purpose of ECS is to maintain balance within an organism.

Endocannabinoid System

In an ideal situation, where all the systems of the body including the circulatory, digestive, endocrine, immune, muscular, nervous, reproductive and respiratory and skeletal system function optimally, this perfect functioning of an organism is called the homeostasis, which can be also understood as a dynamic state of equilibrium.

The endocannabinoid system is a primary “instrument” in charge of maintaining homeostasis, and this is why the cells of all these different systems and tissues have cannabinoid receptors.

In a nutshell, the endocannabinoid system helps to maintain health on a cellular level in every of system of the body, vigilantly reacting and adapting to the continuous changes our body encounters. And most importantly, for this discussion, is that cannabinoid compounds found in the cannabis/marijuana plant ‘feed’ the ECS. Simply put, cannabis is not only a medicine, it could prove to be one of the most important medicines because it fuels the ECS and returns the body to a healthy balance. Read more about the ECS here. Or you can watch a 3 minute YouTube clip below.

We realized that cannabis holds a place in human health care that makes it a once in a generation opportunity, on many levels. In this presentation, we will demonstrate why.

Fast forward to 2019…. Where the cannabis industry is predicted to become a US$500 billion a year industry and now our intense curiosity has become… Medicinal Organic Cannabis Australia (MOCA) Pty Ltd.

As at December 2018, we are now a fully licenced medicinal cannabis (marijuana) company based Sydney, Australia that commenced operations in March 2017 and were awarded import/export licences from the Australian Government in December 2018.

Our core business is in the sourcing, importation and exportation of cannabis oil based medication for use in treating patients suffering from clinical conditions. Our State and Federal licences allow us to service emerging markets in Australia and internationally.

We have undertaken scientific research to source a range of cannabinoid based medical products for treating chemotherapy-induced nausea and vomiting, epilepsy, multiple sclerosis, chronic non-cancer pain and palliative care.

Our Company is now ready to move into importing a range of products under our own brand and starting to manufacture our products for wholesale to the healthcare industry.

Our Continuing Journey

Furthermore, in December 2018, the Company submitted applications to the New Zealand Government for licences to import cannabis products and to establish a research facility to cultivate medical marijuana.

We have developed a key strategic partnership agreement with, a leading medical cannabis digital marketing company to promote our products internationally, on platforms including

We are now ready for the next chapter in our journey with this healing plant and have some ambitious plans for expansion in Australia, New Zealand and internationally.

The capital raised will go towards a number of new business projects including:

1. Importing organic medicinal products under our own brand.

2. Marketing our products to the health care industry

3. Expanding import/export and cultivation opportunities in New Zealand.

4. Supplying our organic MOCA branded medications to an international market.

MOCA has coordinated an interdisciplinary cross-functional team to establish the requirements, evaluate alternatives, develop the business case and implement the solution. The highly skilled and experienced management team has developed an appropriate strategy to build the capabilities and collaborative relationships necessary to capitalize on the opportunities emerging in the medicinal cannabis industry.